Fetal Monitoring Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Ultrasound, Device, Fetal Monitors, Uterine Contraction Monitors, Fetal Electrodes, Fetal Doppler Device, Telemetry Device, Accessories and Consumables, Others), By Portability (Portable System and Non-Portable System), By Method (Invasive and Non-invasive), By Application (Antepartum, Intrapartum), By End User (Hospitals, Obstetrics & Gynecology clinic, Home Care Setting), By Region, & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 6.16 Billion
CAGR (2026-2031)	7.01%
Fastest Growing Segment	Antepartum
Largest Market	North America
Market Size (2031)	USD 9.25 Billion

Market Overview

The Global Fetal Monitoring Market will grow from USD 6.16 Billion in 2025 to USD 9.25 Billion by 2031 at a 7.01% CAGR. Fetal monitoring comprises the continuous assessment of fetal vital signs, specifically heart rate and uterine contractions, to evaluate fetal well-being during gestation and labor. The market is primarily propelled by the increasing prevalence of preterm births and high-risk pregnancies, which necessitate rigorous surveillance to ensure positive health outcomes. Furthermore, the global rise in maternal age has amplified the need for diligent monitoring to manage associated pregnancy complications and mitigate mortality risks. According to the March of Dimes, in 2024, the preterm birth rate in the United States remained at a concerning 10.4%, highlighting the persistent demand for these diagnostic interventions to address critical maternal health issues.

However, a significant challenge impeding market expansion is the substantial cost associated with acquiring and maintaining medical-grade monitoring systems. This financial barrier limits the adoption of necessary equipment in lower-income regions and smaller medical facilities, effectively restricting market penetration. Additionally, the requirement for specialized training to accurately interpret monitoring data creates a bottleneck, as the global shortage of skilled healthcare professionals hinders the universal implementation of these essential safety measures in standard clinical practice.

Key Market Drivers

Advancements in non-invasive and portable monitoring technologies are driving market growth by enabling continuous fetal surveillance outside traditional hospital settings. These wireless innovations track fetal vital signs without tethering patients to bedside monitors, thereby facilitating remote management and improving patient compliance. This technological shift allows for the early detection of complications in high-risk pregnancies without requiring prolonged hospital admissions, effectively bridging the gap between clinical safety and patient mobility. Highlighting this progress, according to GE HealthCare, in February 2024, the company received FDA clearance for its Novii+ monitoring solution, which extends wireless capabilities to a broader range of pregnant patients. This rapid pace of innovation is sustained by substantial capital influx; according to Silicon Valley Bank, in 2024, venture capital investment in the women’s health sector reached $2.6 billion, securing essential resources for the development of such next-generation diagnostic devices.

Supportive government initiatives for maternal and infant health act as a critical catalyst by channeling funds into obstetric infrastructure modernization. Public health agencies are prioritizing investments to reduce mortality rates and address healthcare disparities, directly supporting the procurement of medical-grade monitoring equipment in underserved and rural regions. These programs subsidize the cost of advanced devices and enforce rigorous safety protocols to ensure equitable access to perinatal care. For instance, according to the Health Resources and Services Administration, in October 2024, the agency awarded nearly $19 million to state-led projects specifically aimed at enhancing maternal health outcomes and service delivery. Such strategic public funding lowers financial barriers for medical facilities, directly stimulating the adoption of essential fetal assessment tools across diverse healthcare landscapes.

Download Free Sample Report

Key Market Challenges

The requirement for specialized training and the global shortage of skilled healthcare professionals presents a formidable barrier to the growth of the Global Fetal Monitoring Market. Fetal monitoring systems generate complex physiological data, including fetal heart rate patterns and uterine contractions, which demand advanced clinical expertise for accurate interpretation. The inability to correctly distinguish between benign irregularities and genuine fetal distress can lead to severe adverse health outcomes and significant legal liabilities for medical facilities. This dependency on expert interpretation creates a bottleneck, as the deployment of these diagnostic technologies cannot outpace the availability of trained personnel competent in their operation and analysis.

Consequently, the scarcity of qualified obstetricians and midwives directly restricts the scalability of monitoring services, particularly in regions facing acute workforce deficits. Medical facilities are often forced to limit the adoption of advanced monitoring solutions due to insufficient staffing levels required to maintain rigorous surveillance standards. According to the 'American College of Obstetricians and Gynecologists', in '2025', the national supply of obstetrician-gynecologists in the United States met only 93.4% of the demand. This widening gap between workforce supply and clinical demand hampers the universal implementation of essential safety measures, thereby stalling market expansion.

Key Market Trends

The integration of Artificial Intelligence (AI) for predictive fetal analytics is revolutionizing the market by moving beyond simple data logging to real-time risk stratification. Algorithms now analyze complex heart rate patterns to identify distress earlier, supporting clinical decision-making for preterm and high-risk pregnancies. This shift is exemplified by regulatory milestones that validate AI's role in extending surveillance capabilities to more vulnerable gestational stages. According to PeriGen, February 2025, the company received FDA clearance for its Patterns 3.0 software, which expanded its AI-powered pattern recognition technology to include fetuses as early as 32 weeks gestation. Such advancements allow clinicians to proactively manage critical cases with greater precision, reducing the reliance on subjective interpretation that often creates bottlenecks in acute care settings.

Simultaneously, the proliferation of smartphone-compatible smart monitoring devices is decentralizing prenatal care, allowing expectant mothers to perform clinical-grade assessments at home. These handheld solutions interface directly with mobile applications, transmitting images and data to medical teams for remote review, thereby reducing the burden of frequent clinic visits. This trend of consumer-centric, connected care was solidified when, according to Pulsenmore, November 2025, the company received FDA De Novo marketing authorization for its home-use prenatal ultrasound platform, which utilizes a smartphone-connected cradle to enable patient-led scanning. This capability effectively addresses care deserts by bridging the physical distance between patients and obstetricians while maintaining a continuous stream of diagnostic-quality data.

Segmental Insights

Based on recent market research, the Antepartum segment is identified as the fastest-growing category within the Global Fetal Monitoring Market. This rapid expansion is primarily driven by the increasing prevalence of congenital anomalies and genetic disorders, which necessitates early and frequent fetal assessment throughout the gestation period to ensure favorable pregnancy outcomes. Furthermore, the rising incidence of high-risk pregnancies, attributed to factors such as advanced maternal age and lifestyle-related conditions, has intensified the demand for continuous prenatal surveillance. Adherence to clinical guidelines from organizations like the American College of Obstetricians and Gynecologists regarding early detection of fetal distress further accelerates the adoption of advanced antepartum monitoring solutions globally.

Regional Insights

North America leads the Global Fetal Monitoring Market primarily due to its established healthcare infrastructure and substantial healthcare expenditure. The region benefits from high patient awareness regarding maternal health and favorable reimbursement policies that facilitate access to care. Furthermore, the United States Food and Drug Administration plays a critical role in maintaining high safety standards, which encourages trust and adoption of new devices. The presence of key industry players within the region also supports continuous product availability, securing North America’s position as the dominant market globally.

Recent Developments

• In February 2025, Philips announced a collaborative program with Amerigroup, CareSource Georgia, and Peach State Health Plan to provide remote patient monitoring for pregnant and postpartum individuals in Georgia. The initiative focused specifically on patients with maternal hypertension and diabetes, aiming to improve access to care in a region with high rates of maternal mortality and morbidity. The program utilized the company's monitoring technology to track vital signs and included personalized health coaching from licensed clinical professionals. Participants received alerts if their physiological data fell out of range, allowing for timely intervention by healthcare providers to help prevent serious complications.
• In April 2024, Raydiant Oximetry announced that the U.S. Food and Drug Administration had approved an Investigational Device Exemption for its Lumerah technology, allowing the company to initiate an Early Feasibility Study with pregnant women. The technology was described as a non-invasive fetal pulse oximeter designed to improve the detection of fetal distress during labor and delivery by measuring fetal blood oxygen saturation directly. The company emphasized that this breakthrough could potentially reduce medically unnecessary Cesarean sections and newborn neurological injuries by providing more accurate diagnostic data than traditional fetal heart rate monitors currently available in the market.
• In February 2024, GE HealthCare received 510(k) clearance from the U.S. FDA for its Novii+ Wireless Patch Solution, an advanced maternal and fetal monitoring platform. This system was designed to provide non-invasive measurement and display of fetal heart rate, maternal heart rate, and uterine activity for patients at or beyond 34 weeks of pregnancy. The company noted that the belt-free, wire-free design allowed mothers greater mobility and freedom during labor, which could potentially decrease the length of labor. The updated solution incorporated a new artifact reduction algorithm intended to improve the reliability and accuracy of the monitoring data provided to care teams.
• In January 2024, Bloomlife announced that it had received clearance from the U.S. Food and Drug Administration for its MFM-Pro device, marking a significant transition for the company from consumer to medical markets. This prescription-based wearable system was designed to allow healthcare providers to measure maternal and fetal heart rates in both home and clinical settings. The device utilized non-invasive technology to measure the body's electrical activity and employed cloud-based processing to accurately extract heart rate data. The company stated that this development aimed to shift care from high-cost clinical settings to the home, addressing the need for better support in high-risk pregnancies.

Key Market Players

• Medtronic Plc
• Cardinal Health Inc.
• Koninklijke Philips N.V.
• Siemens Healthineers AG
• GE Healthcare Technologies Inc.
• FUJIFILM SonoSite, Inc
• Natus Medical Incorporated
• Huntleigh Healthcare Limited
• CooperCompanies Inc.
• CONTEC Medical Systems Co., Ltd

By Product	By Portability	By Method	By Application	By End User	By Region
Ultrasound Device Fetal Monitors Uterine Contraction Monitors Fetal Electrodes Fetal Doppler Device Telemetry Device Accessories and Consumables Others	Portable System and Non-Portable System	Invasive and Non-invasive	Antepartum Intrapartum	Hospitals Obstetrics & Gynecology clinic Home Care Setting	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Fetal Monitoring Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Fetal Monitoring Market, By Product:

• Ultrasound
• Device
• Fetal Monitors
• Uterine Contraction Monitors
• Fetal Electrodes
• Fetal Doppler Device
• Telemetry Device
• Accessories and Consumables
• Others

• Fetal Monitoring Market, By Portability:

• Portable System and Non-Portable System

• Fetal Monitoring Market, By Method:

• Invasive and Non-invasive

• Fetal Monitoring Market, By Application:

• Antepartum
• Intrapartum

• Fetal Monitoring Market, By End User:

• Hospitals
• Obstetrics & Gynecology clinic
• Home Care Setting

• Fetal Monitoring Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE